CAMBRIDGE, Mass., Aug. 21, 2024 /PRNewswire/ -- GV20 Therapeutics, a clinical-stage AI and genomics-based next generation biotherapeutics company announced today that Dr. Kristopher Wentzel from The Angeles Clinic and Research Institute will present the clinical data on GV20-0251 monotherapy dose escalation at the ESMO Congress 2024, taking place in Barcelona on Sept 13-17, 2024.

马萨诸塞州剑桥市，2024年8月21日/PRNewswire/--GV20 Therapeutics，一家基于临床阶段AI和基因组学的下一代生物治疗公司今天宣布，来自洛杉矶诊所和研究所的Kristopher Wentzel博士将在2024年9月13日至17日在巴塞罗那举行的2024年ESMO大会上介绍GV20-0251单药治疗剂量递增的临床数据。

GV20-251 is the first clinical stage, AI-designed antibody therapeutic against an AI-predicted target in the clinic. The monotherapy dose escalation study started on Mar 27, 2023, and has enrolled across six dose cohorts and two schedules. GV20-0251 has shown favorable safety profile and promising monotherapy clinical efficacy..

GV20-251是临床上针对AI预测靶标的AI设计的抗体治疗的第一个临床阶段。单药治疗剂量递增研究始于2023年3月27日，已纳入六个剂量组和两个时间表。GV20-0251显示出良好的安全性和有希望的单一疗法临床疗效。。

Details of the oral presentation are below:

口头演示的详细信息如下：

Title: 'A phase 1/2, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors'Session Type: Mini oral sessionSession Title: Investigational ImmunotherapySession Date/Time: Monday Sep 16, 2024, 10:15-11:45AMSession Room: Granada Auditorium - Hall 6Presentation Number: 1000MO.

标题：“新型检查点IGSF8抑制剂GV20-0251在晚期实体瘤患者中的1/2期开放标签研究”会议类型：小型口腔会议会议标题：研究性免疫治疗会议日期/时间：2024年9月16日星期一，10:15-11:45上午会议室：格拉纳达礼堂-6号厅会议编号：1000MO。

ABOUT GV20 THERAPEUTICS

关于GV20疗法

GV20 Therapeutics is developing a differentiated pipeline of next generation biotherapeutics integrating AI, genomics, & disease biology. Our lead program, GV20-0251, a first-in-class, fully human, Fc-attenuated IgG1 monoclonal antibody targeting a novel immune checkpoint IGSF8 to activate innate and adaptive immunity, is in a multi-center Phase 1/2 clinical trial in patients with advanced solid tumors (NCT05669430).

GV20 Therapeutics正在开发一种整合AI，基因组学和疾病生物学的下一代生物治疗药物的差异化管道。我们的主要项目GV20-0251是针对新型免疫检查点IGSF8激活先天性和适应性免疫的一流，全人类Fc减毒IgG1单克隆抗体，正在进行多中心1/2期临床试验，用于晚期实体瘤患者（NCT05669430）。

Our discovery pipeline includes best-in-class and first-in-class ADCs and degraders. GV20 is headquartered in Cambridge, MA..

。GV20总部位于马萨诸塞州剑桥。。

To learn more about GV20, please visit https://gv20tx.com/ and follow the company on LinkedIn.

要了解有关GV20的更多信息，请访问https://gv20tx.com/并在LinkedIn上关注该公司。

Business ContactYing Gong, Ph.D., CBOBD@gv20tx.com

商务联系人龚颖，博士。，CBOBD@gv20tx.com

SOURCE GV20 Therapeutics

来源GV20 Therapeutics